An Evaluation of Pain Response in between 800 Cgy Single Fraction Radiotherapy


Cancer that begins in an organ and then spreads to bone is called metastatic bone disease. This is a very commonly encountered problem in oncology practice as bone metastasis is a common cause of mild to severe grade of pain and other significant symptoms that are detrimental to quality of life of patients. Sometimes bone metastasis is a common manifestation of distant relapse from many types of solid malignancies especially from cancers of the lung, breast and prostate. The exact incidence of bone metastases is difficult to determine, but evidence suggests that more than 100,000 people in the United States develop osseous metastatic disease annually. The axial skeleton is the most common site of bone metastasis, with metastasis most frequently occurring in the spine, pelvis, and ribs. Among them, spinal metastasis contributes upto 65% and the lumber spine is the most frequent site of spinal metastasis. In the appendicular skeleton, the proximal femurs are the most common site of metastatic disease, and humeral lesions also occur frequently. The acral sites (feet and hands) are rarely involved. The ultimate prognosis for patients with bone metastases is poor, with median survival typically measured in months rather than years. Overall survival depends on the primary site and the presence or absence of visceral metastases. Patients with bone metastases from lung cancer have short median survival with a duration of 6 months. However, patients with bone metastases from breast or prostate primary sites may have significantly longer survival times. In patients with bone-only metastatic prostate or breast cancer, median survivals of 2 to 4 years have been reported.